Pharmaceutical intermediates
Sparsentan Intermediates
6 pharmaceutical intermediates for Sparsentan. Indication: Glomerulosclerosis, Focal Segmental;Glomerulonephritis, IGA.
About Sparsentan
- Originator
- Bristol Myers Squibb
- Indication
- Glomerulosclerosis, Focal Segmental;Glomerulonephritis, IGA
- Approved Date
- 02/17/2023
- NCE Patent
- 02/17/2028
- DS/DP
- 03/29/2030
Available intermediates
6 intermediates currently listed for Sparsentan. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid | 415697-58-4 | / | / |
| N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide | 415697-56-2 | / | / |
| 4-bromo-3-(ethoxymethyl)benzaldehyde | 837408-71-6 | / | / |
| 4-bromo-3-ethoxymethyl-benzoic acid ethyl ester | 948349-66-4 | / | / |
| N-(4,5-Dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-formyl-N-(methoxymethyl)[1,1'-biphenyl]-2-sulfonamide | 1026913-68-7 | / | / |
| N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide | 1098924-76-5 | / | / |
Building toward Sparsentan?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →